172 results
Page 6 of 9
8-K
EX-99.1
wqcoxq 4iw3tkntm0nox
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
bxvh1
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-99.1
okoh bhfuh
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
d36u x0u7tgojdacznp
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-10.1
0s7jj1r23ro678x iqoy
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
ledzq2v dvtn
1 Aug 19
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
7:23am
8-K
EX-99.1
a8kgi
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-99.1
x0356xbboawjt02krvog
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
ytysi2
22 Jul 19
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
8:08am
8-K
EX-99.1
2pw851 duhqz982
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-10.1
d1kta4s71 vaprru
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
ofzv0s91zo5df43h3rkd
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
mkmnfrb 3xthhij4yw25
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
umrdpteibfwl13
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
wfpq2hjqowioq17u1
6 May 19
Adaptimmune Reports First Quarter 2019 Financial Results
7:38am
8-K
EX-99.1
g95vflrhm4mwp9c0nsd3
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am